Ro and Modern Weight Management
Ro and Modern Weight Management
Scientific evidence on GLP1 medicines and online care
Ro is a tele-health service that can connect eligible people with prescription weight-management treatment. It is not a new GLP-1 medicine. That distinction matters: choosing a care provider and choosing a medication are related decisions, but they require different evidence.
Randomized trials support substantial average weight loss with several incretin-based medicines. Some products also improve specific cardiovascular, sleep-apnea or liver outcomes in defined populations. Those findings do not prove that one online platform delivers better care than another. A useful comparison considers the exact product, medical suitability, follow-up, nutrition support, affordability and a realistic long-term plan.
This article examines Ro, the science behind the main approved options, and how Ro compares with other US care services. It is a narrative evidence review, not a systematic review or a personal prescribing recommendation. Priority is given to regulatory information and original clinical studies; company pages are used for service terms and advertised prices. Evidence and product availability continue to change.
What readers should take away
Medication trials and platform reviews answer different questions. Mean weight-loss percentages are not personal forecasts. An introductory membership fee is not the total treatment cost. Effective care should monitor health and function, not only the number on the scale.
The doses described in this article identify studied treatments. They are not instructions for starting, escalating, combining or switching medication. Treatment decisions require a licensed clinician who knows the person's history.
What Ro provides and what its evidence shows
Ro's advertised program includes clinician assessment, ongoing messaging and check-ins, dose and side-effect management, and insurance assistance for eligible products. Medication is charged separately. Availability depends on medical eligibility, location and the treatment pathway. These are descriptions of the service, not independent measurements of care quality. [1]
The current menu includes Wegovy tablets and injections, the higher-dose Wegovy HD injection, Foundayo tablets and Zepbound presentations. An online menu is not a promise that every person will qualify for every product. The prescription should identify the ingredient, brand, formulation and dispensing pharmacy. [2]
A closer look at the Ro study
A peer-reviewed retrospective study sampled 4,500 people who started semaglutide through Ro. Among 655 with a weight recorded near week 68, average loss was 16.6%. The substantial missing follow-up, absence of a randomized provider comparator and company-linked investigators limit the conclusion. Most authors reported Ro employment or equity. This result describes a selected group with follow-up data; it does not establish the outcome for every starter or show that Ro outperforms another platform. [4]
The practical implication is to ask about retention and follow-up, as well as the headline percentage. Who remains in the analysis? What happened to those who stopped because of cost, side effects or lack of response? Were weights measured or self-reported? A large percentage without this context can be misleading.
How to interpret the Forbes review
The Forbes article that prompted this review describes one tester's mixed experience and carries an advertiser-compensation disclosure. It is useful for identifying consumer questions about communication, billing and insurance support. It is not a clinical trial, a representative patient survey or a direct test of competing providers. Its service details should be checked against current terms before enrollment. [5]
There is no basis in the evidence reviewed here to award Ro a universal clinical-quality ranking. Convenience may be valuable, but the relevant question is whether a particular service can deliver safe, responsive and sustainable care for the person using it.
How these medicines work
GLP-1 receptor agonists act on pathways involved in appetite, food intake and glucose regulation. Delayed stomach emptying is one action, but it is not a complete explanation of long-term weight loss. Tirzepatide activates both GIP and GLP-1 receptors. Orforglipron is a small-molecule GLP-1 receptor agonist; it is not oral tirzepatide. [6,7,16]
These are prescription treatments for defined medical indications. Adult obesity studies commonly enrolled people with a body mass index of at least 30, or at least 27 with a weight-related condition. Eligibility requires more than matching a BMI threshold: medical history, contraindications, other medicines and the purpose of treatment all matter. [12,13]
Names and formulations
| Weight-management brand | Ingredient | Route and distinction |
| Wegovy | Semaglutide | Weekly injection or daily tablet; formulations have separate instructions |
| Wegovy HD | Semaglutide | 7.2 mg weekly injection option for selected adults; not a starting dose |
| Zepbound | Tirzepatide | Weekly injection; dual GIP and GLP-1 activity |
| Saxenda | Liraglutide | Daily injection |
| Foundayo | Orforglipron | Daily tablet; maximum marketed strength 17.2 mg |
Current US prescribing information and FDA approval notices support this map. Brand availability through a particular service may differ. [6–9,34,35]
Ozempic and Mounjaro are diabetes-branded semaglutide and tirzepatide products, respectively, with additional indication-specific benefits. They are not FDA-approved specifically for weight management. Current Ozempic labeling includes tablets as well as injection; older comparisons describing it only as a shot are incomplete. Rybelsus is another diabetes-branded oral semaglutide product. A shared ingredient does not make brands or milligram doses interchangeable. [10,11,36]
What is new in the current comparison
Oral Wegovy has a morning fasting routine, whereas Foundayo can be taken with or without food. Wegovy HD adds a higher weekly injection option for selected adults. These differences can affect daily practicality, but do not identify the best treatment for everyone. Oral products still have adverse effects, interactions and eligibility requirements. [6,9,34,35]
What randomized trials found
The table reports mean loss as a percentage of starting body weight, using the published papers' main analyses. All trials listed below enrolled adults without diabetes and included lifestyle support. These are separate trials, with different populations, durations and methods; the rows are not a ranking. [12–17]
| Trial and treatment | Participants and duration | Mean body-weight loss |
| STEP 1 • Semaglutide 2.4 mg weekly | 1,961; 68 weeks | 14.9% vs 2.4% placebo |
| SURMOUNT-1 • Tirzepatide 5, 10 or 15 mg weekly | 2,539; 72 weeks | 15.0%, 19.5%, 20.9% respectively; placebo 3.1% |
| SCALE • Liraglutide 3 mg daily | 3,731; 56 weeks | 8.0% vs 2.6% placebo |
| OASIS 4 • Oral semaglutide 25 mg daily | 307; 64-week weight endpoint | 13.6% vs 2.2% placebo |
| ATTAIN-1 • Orforglipron daily | 3,127; 72 weeks | 11.2% at highest trial dose vs 2.1% placebo |
| STEP UP • Semaglutide 7.2 mg vs 2.4 mg weekly | 1,407; 72 weeks | 18.7% vs 15.6%; placebo 3.9% |
ATTAIN-1's highest investigational capsule dose was 36 mg; its equivalent approved marketed tablet dose is 17.2 mg. Do not mistake the research formulation for a current prescription strength. [9,16]
Why apparently similar percentages differ
An estimand defines the question a trial's analysis answers. Treatment-policy or treatment-regimen analyses generally aim to estimate outcomes despite stopping assigned treatment, using specified methods for missing data and other events. Trial-product or efficacy estimands ask a more hypothetical question about continued treatment. They should not be mixed casually in marketing comparisons.
For example, OASIS 4 reported 13.6% under its primary treatment-policy analysis and 16.6% under a trial-product analysis. Both refer to the same study but different assumptions. SCALE used an older last-observation-carried-forward method. Even regulatory tables can differ slightly from journal analyses: the Foundayo label reports 11.1% for the highest equivalent marketed dose, whereas ATTAIN-1's paper reports 11.2%. [9,14–16]
Direct comparisons and benefits beyond weight
The direct tirzepatide and semaglutide comparison
SURMOUNT-5 randomized 751 adults without type 2 diabetes to maximum tolerated weekly tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg. At 72 weeks, mean loss was 20.2% versus 13.7%, an estimated 6.5 percentage-point difference. The trial was open-label and Lilly-funded; its primary analysis used a modified treatment-regimen estimand. [18]
This is stronger comparative evidence than placing two unrelated trial percentages next to each other. It supports greater average weight loss with tirzepatide under the tested conditions. It did not compare semaglutide 7.2 mg, oral Wegovy, Foundayo, compounded products or telehealth providers. Tolerability, contraindications, access and individual response still influence treatment choice. [18]
STEP UP separately compared semaglutide 7.2 mg with 2.4 mg and placebo. Its findings support an incremental average weight-loss benefit of the higher dose in the studied population. They do not establish how 7.2 mg performs against tirzepatide. [17]
Cardiovascular outcomes need population context
SELECT enrolled 17,604 adults aged at least 45 with established cardiovascular disease, overweight or obesity, and no diabetes. During a mean 39.8 months, major cardiovascular events occurred in 6.5% receiving semaglutide 2.4 mg and 8.0% receiving placebo. The hazard ratio was 0.80, with a 95% confidence interval of 0.72–0.90. [19]
That means a 20% lower relative hazard and a 1.5 percentage-point difference in observed event proportions. It does not mean 20 percentage points fewer events, or prove the same benefit in someone without established cardiovascular disease. Absolute benefit depends on baseline risk. [19]
Other indications also remain product- and population-specific. Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy injection has an accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis, based on liver endpoints with confirmatory clinical benefit still required. Neither statement means all sleep apnea or all fatty liver disease is treated the same way. [20,21]
Compare online care services separately
These advertised US membership terms were checked on 14 October 2026. They describe access and billing, not a clinical-quality league table. Medicine, eligibility, state availability and insurance arrangements can differ.
| Service | Advertised service fee | What to check |
| Ro | $39 first month; then $149 monthly, or $74 per month equivalent with annual prepayment | Medicine extra; lower fee requires commitment; insurance support is product-specific |
| Hers | $39 first month; then $149 per month | Medicine extra; auto-renewal; canceling membership ends the medication plan and care access |
| WW Med+ | $25 first month; then $74 monthly on a 12-month term or $84 on a 6-month term | GLP-1 medicine extra; term commitment and renewal conditions |
| Noom Med | Plan-specific; branded and compounded pathways use different pricing structures | Confirm the exact program, whether medicine is bundled, and the amount billed upfront |
Sources are each provider's own terms. Noom's branded and bundled compounded programs should not be collapsed into one comparable price. [2,22–24,37]
Ro advertises ongoing clinical messaging and insurance coordination. Hers describes tracking, medication adjustments and side-effect support. WW Med+ combines clinical care with its behavior-support program. These may be useful features, but advertised availability is not the same as measured response time, continuity or outcomes. [1,22,23]
A local primary-care clinician or obesity-medicine specialist is another route. Compare the actual visit cost, insurance coverage and follow-up arrangements available to you. There is no universal online-versus-in-person winner; the useful comparison is the care that can be delivered reliably.
Ask how outcomes were measured
Platform claims based on engaged users or people reporting follow-up weights can be affected by selection, adherence and missing data. People who remain in a program may differ from those who leave. Comparing one company's selected completers with another drug's randomized trial is not a valid provider comparison.
Similarly, an approved branded product does not establish that every advertised low-dose or “microdosing” regimen produces the benefits observed at studied doses. Ask which evidence supports the proposed regimen, rather than assuming a label-approved ingredient validates every dosing strategy.
Understand the ongoing cost
Ro charges separately for membership and medication. Its $39 introductory membership therefore should not be read as a $39 all-inclusive treatment. A useful budget is the continuing service fee plus the actual prescribed product, with any additional applicable charges. [1,2]
A transparent example
| Item | Illustrative monthly cost |
| Ro month-to-month membership after introductory month | $149 |
| Advertised cash price for Wegovy pen at 2.4 mg | $349 |
| Combined monthly amount | $498 |
This is arithmetic using advertised terms on 14 October 2026, not an individualized quote. A different dose, medicine, membership commitment or insurance arrangement changes the amount. Introductory medicine offers may apply only to early doses or limited periods. [2,38]
Ro's insurance page states that membership is not insurance-covered and that insurance assistance is available for specified products, including Wegovy pen, Zepbound autoinjector and Ozempic. Assistance with authorization does not guarantee coverage. Government-plan and other exclusions require an individual check. [3]
Before agreeing to a plan
Ask for the total cost after the introduction ends and at the expected continuing dose. Check whether a low “per month” figure means a large prepaid amount. Read cancellation and renewal terms, and ask what happens to prescribing support if membership ends. Request a plan for coverage denial, supply interruption or a medicine change.
This is part of clinical decision-making, not simply shopping. A treatment that becomes unaffordable after escalation can disrupt continuity. Price comparisons are most useful when they describe the same type of product, similar follow-up and the same time horizon.
Safety and reproductive planning
Gastrointestinal effects such as nausea, vomiting, diarrhea and constipation are common. Important precautions include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal symptoms and allergic reactions. Hypoglycemia risk is greater with insulin or insulin-secretagogue combinations. Product-specific details and other interacting medicines require review. [8]
These medicines are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2, or serious hypersensitivity to the specific drug or its ingredients. This does not exclude every thyroid disorder. They are not recommended in severe gastroparesis. Tell the care team about planned anesthesia or deep sedation. [8]
Severe or persistent abdominal pain, repeated vomiting or inability to retain fluids calls for prompt assessment. Severe allergic symptoms or sudden vision loss requires urgent care. Persistent inability to eat or drink should not be treated as evidence that weight-loss treatment is succeeding. These examples do not replace the full medication guide. [7,29]
Pregnancy and contraception
Weight-loss medicines are not used during pregnancy. For semaglutide weight reduction, stop when pregnancy is recognized and at least two months before a planned pregnancy. Tirzepatide users taking oral contraceptives should use a nonoral method or add a barrier method for four weeks after starting and after each dose increase. For Foundayo, use the same protection for 30 days after starting and after each dose increase. Discuss pregnancy, breastfeeding and contraception before treatment. [6,7,9]
Two safety updates that deserve accurate wording
In January 2026, FDA requested removal of suicidal-behavior and ideation warnings from relevant GLP-1 weight-loss labels after its review found no increased risk. Older summaries that present such a causal link as established are out of date. New mental-health symptoms still deserve care. [28]
European regulators classified nonarteritic anterior ischemic optic neuropathy, or NAION, as a very rare semaglutide adverse effect, up to one in 10,000. This is an EMA assessment, not a claim that every GLP-1 drug has an identical risk or that this wording appears in every US label. Sudden vision change needs urgent evaluation regardless of the cause. [29]
Compounded products require a separate discussion
A compounded preparation is not an FDA-approved generic equivalent. FDA does not review these preparations for safety, effectiveness and quality before marketing. Semaglutide sodium and acetate are different active ingredients from the one in approved products; they should not be assumed equivalent. Products offered for research use only are not a safe consumer treatment route. [25]
The shortage-based environment has changed. FDA determined the tirzepatide injection shortage resolved in December 2024 and the semaglutide injection shortage in February 2025; related transition periods ended in 2025. Routine copies cannot simply rely on those former shortages. Limited patient-specific compounding exceptions have requirements, including a prescriber-documented significant difference for an identified patient where applicable. Adding vitamin B12 or advertising a custom dose does not automatically establish an exception. [26]
Ask what is being prescribed, why an approved product cannot meet the medical need, and which state-licensed pharmacy dispenses it. Vial concentrations and measuring instructions can differ. A syringe “unit” is not a universal medication dose; obtain product-specific instructions from the clinician and pharmacist. FDA has reported dosing errors with compounded semaglutide, including cases requiring hospitalization. [25,27]
Protect nutrition and physical function
Weight loss can include both fat and lean tissue. In the 160-person SURMOUNT-1 DXA substudy, approximately three quarters of lost weight was fat and one quarter lean mass. These are proportions of weight lost, not a claim that one quarter of a person's muscle disappeared. DXA lean mass includes tissue other than skeletal muscle, and the substudy does not predict a fixed result for every patient. [30]
The 2025 joint nutrition advisory emphasizes nutritional assessment, adequate intake, individualized protein and resistance training. Protein alone does not replace strength training. Practical priorities include regular nutrient-dense meals, fluids and early help with symptoms that impair eating. Needs vary with age, medical conditions and activity; a blanket protein or calorie target is inappropriate. [31]
Track strength, energy, recovery and food tolerance alongside body weight. A falling scale weight is not the only definition of progress. Persistent weakness, poor intake or worsening exercise tolerance should prompt review with the prescribing team and a qualified nutrition professional.
Plan for maintenance before stopping
Medication withdrawal studies support treating obesity as a condition that often needs ongoing management. They do not establish a single permanent regimen for everyone.
In the STEP 1 extension, a subset of 327 participants was followed after both semaglutide and structured lifestyle intervention stopped. Over the following year, participants formerly receiving semaglutide regained about two thirds of their prior average loss. This was an exploratory subset, not a prediction that every person regains exactly that amount. [32]
SURMOUNT-4 offers a randomized withdrawal comparison. After a 36-week tirzepatide lead-in, 670 participants were randomized to continue or switch to placebo for 52 weeks. Those switched to placebo gained 14.0% from their weight at randomization; those continuing lost a further 5.5%. Lifestyle counseling continued in both groups. The 14.0% is a percentage of week-36 body weight, not the fraction of earlier weight loss regained. [33]
The clinical lesson is to plan maintenance, access, tolerability and follow-up early. Regain after withdrawal is not evidence of a character flaw. If treatment needs to change, the care plan should change with it.
Questions to bring to a consultation
1. Which exact medicine and formulation fits my health history and treatment goals?
2. Is the product FDA-approved, and is the proposed use consistent with its indication?
3. What contraindications, interactions, pregnancy plans or procedure risks need review?
4. What is the ongoing total cost, and what happens if insurance or supply changes?
5. Who manages side effects, how quickly can I reach them, and where do urgent concerns go?
6. How will nutrition, physical function and treatment response be monitored?
7. What are the maintenance and follow-up options if I stop or switch treatment?
Ro may be a useful access route for an eligible person who values remote care. The evidence supports evaluating it on the quality and continuity of that service, while evaluating the prescribed medicine on its own trials, label and personal suitability. An informed choice joins those two assessments.
US edition • Research and advertised prices checked Oct 2026
References
Numbered citations link the article to original studies, prescribing information and current service terms. All web sources were checked on 14 October 2026. Company pricing and product labels may change after this date.
[1] Ro. How the weight loss program works. View source
[2] Ro. Weight loss program pricing. View source
[3] Ro. Weight loss program and insurance. View source
[4] Tchang BG et al. Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth. Obesity. 2026;34:729–737. View source
[5] Borst H. Ro Body Weight Loss Medication Review. Forbes Health. May 2026. Consumer review and advertiser disclosure. View source
[6] Novo Nordisk. Wegovy prescribing information. Revised June 2026. View source
[7] Eli Lilly. Zepbound prescribing information. Revised August 2026. View source
[8] Novo Nordisk. Saxenda prescribing information. View source
[9] FDA. Foundayo prescribing information. April 2026. View source
[10] Novo Nordisk. Ozempic injection prescribing information. View source
[11] Eli Lilly. Mounjaro prescribing information. Revised August 2026. View source
[12] Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989–1002. View source
[13] Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387:205–216. View source
[14] Pi-Sunyer X et al. A Randomized Controlled Trial of 3.0 mg of Liraglutide in Weight Management. NEJM. 2015;373:11–22. View source
[15] Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. NEJM. 2025;393:1077–1087. View source
[16] Wharton S et al. Orforglipron an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM. 2025;393:1796–1806. View source
[17] Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity STEP UP. Lancet Diabetes Endocrinol. 2025;13:949–963. View source
[18] Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. NEJM. 2025;393:26–36. View source
[19] Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM. 2023;389:2221–2232. View source
[20] FDA. FDA Approves First Medication for Obstructive Sleep Apnea. December 2024. View source
[21] FDA. FDA Approves Treatment for Serious Liver Disease Known as MASH. August 2025. View source
[22] Hers. Weight Loss FAQs. View source
[23] WeightWatchers. Med+ weight loss medication program and offer terms. View source
[24] Noom. Zepbound program. View source
[25] FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. View source
[26] FDA. Policies for Compounders as National GLP-1 Supply Begins to Stabilize. View source
[27] FDA. Dosing Errors Associated with Compounded Injectable Semaglutide Products. View source
[28] FDA. Request to Remove Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonists. January 2026. View source
[29] EMA. PRAC Concludes NAION Is a Very Rare Side Effect of Semaglutide Medicines. June 2025. View source
[30] Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. View source
[31] Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity a joint advisory. Am J Clin Nutr. 2025. View source
[32] Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide the STEP 1 trial extension. Diabetes Obes Metab. 2022. View source
[33] Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity SURMOUNT-4. JAMA. 2024;331:38–48. View source
[34] FDA. Approval of Higher Dose Semaglutide. March 2026. View source
[35] FDA. Approval of Foundayo. April 2026. View source
[36] Novo Nordisk. Ozempic tablets and Rybelsus prescribing information. View source
[37] Noom. GLP-1Rx program. View source
[38] Ro. Wegovy cost by presentation and dose. View source